Based upon the challenges with toxicity and dosing, as well as the limited efficacy signals observed, the phase II portion of this phase Ib/II trial was not initiated and the development of this particular drug combination for uveal melanoma discontinued; however, the therapeutic strategy of optimizing PKC inhibition in advanced uveal melanoma alone or in combination with other agents remains of great interest. The gene discussed is PRRT2; the disease is uveal melanoma.